Chelsea Price - phaware® interview 464
I'm Aware That I'm Rare: the phaware® podcast
Chelsea Price shares her experience living with pulmonary arterial hypertension (PAH). She emphasizes the importance of having a good support system, including her church community and connecting with other friends with PAH. Chelsea is grateful for the good days she has and strives to be an active mom for her children. Learn even more about Chelsea and PAH at . My name is Chelsea Price. I live in St. Louis, Missouri, and I have pulmonary arterial hypertension (PAH). Shortly after I had my second son, I noticed that my endurance had decreased. I grew up playing soccer, competitive...
info_outline
Episode 464 - Chelsea Price
I'm Aware That I'm Rare: the phaware® podcast
In this episode, Chelsea Price shares her experience living with pulmonary arterial hypertension (PAH). She emphasizes the importance of having a good support system, including her church community and connecting with other friends with PAH. Chelsea is grateful for the good days she has and strives to be an active mom for her children. Discover even more about Chelsea and PAH at Learn more about pulmonary hypertension trials at . Follow us on social @phaware Engage for a cure: #phaware Share your story:
info_outline
Rajan Saggar, MD - phaware® interview 463
I'm Aware That I'm Rare: the phaware® podcast
Dr. Rajan Saggar, a pulmonologist at the University of California in Los Angeles, discusses the complications of pulmonary hypertension in various lung diseases. He explains that pulmonary hypertension can either be its own disease or can complicate other conditions such as heart disease or lung tissue diseases like emphysema or fibrosis. Dr. Saggar mentions a recent FDA-approved medication for pulmonary hypertension complicating lung tissue diseases, and ongoing research to develop more treatments. My name is Rajan Saggar. I'm a pulmonologist. I work out of the University of California in...
info_outline
Episode 463 - Rajan Saggar, MD
I'm Aware That I'm Rare: the phaware® podcast
In this episode, Dr. Rajan Saggar, a pulmonologist at the University of California in Los Angeles, discusses the complications of pulmonary hypertension in various lung diseases. He explains that pulmonary hypertension can either be its own disease or can complicate other conditions such as heart disease or lung tissue diseases like emphysema or fibrosis. Dr. Saggar mentions a recent FDA-approved medication for pulmonary hypertension complicating lung tissue diseases, and ongoing research to develop more treatments. Learn more about pulmonary hypertension trials at . Follow us on...
info_outline
Sandeep Sahay, MD - phaware® interview 462
I'm Aware That I'm Rare: the phaware® podcast
Dr. Sandeep Sahay, a pulmonologist at Houston Methodist Hospital, discusses the concept of disease modification in the treatment of pulmonary hypertension (PH). He explains how traditional PH therapies focus on vasodilation, reducing pressure in the pulmonary artery by dilating blood vessels. However, newer therapies, such as sotatercept, work in different ways to reduce smooth muscle proliferation and thickness of the artery walls. Dr. Sahay suggests that if a drug is labeled as disease-modifying, it may be used in combination with existing PH medications from the beginning of treatment....
info_outline
Episode 462 - Sandeep Sahay, MD
I'm Aware That I'm Rare: the phaware® podcast
In this episode, Dr. Sandeep Sahay, a pulmonologist at Houston Methodist Hospital, discusses the concept of disease modification in the treatment of pulmonary hypertension (PH). He explains how traditional PH therapies focus on vasodilation, reducing pressure in the pulmonary artery by dilating blood vessels. However, newer therapies, such as sotatercept, work in different ways to reduce smooth muscle proliferation and thickness of the artery walls. Dr. Sahay suggests that if a drug is labeled as disease-modifying, it may be used in combination with existing PH medications from the beginning...
info_outline
UNISUS PAH Clinical Trial - phaware® interview 461
I'm Aware That I'm Rare: the phaware® podcast
SPECIAL EDITION Jonathan Hudson is a Global Trial Leader in Pulmonary Hypertension at Janssen Research & Development and is accompanied by colleague Josephine Garcia-Ferrer, Ph.D and Medical Manager. Jonathan and Josephine discuss Pulmonary Arterial Hypertension (PAH), the importance of clinical trials, what they entail, and share information on Janssen’s . Learn more about UNISUS Study with the . Steve Van Wormer: Hello, and welcome to, I’m Aware That I’m Rare, the phaware® podcast. I’m your host, Steve Van Wormer, from Phaware Global Association. Today, I am...
info_outline
Episode 461 - UNISUS PAH Clinical Trial
I'm Aware That I'm Rare: the phaware® podcast
SPECIAL EDITION: Jonathan Hudson is a Global Trial Leader in Pulmonary Hypertension at Janssen Research & Development and is accompanied by colleague Josephine Garcia-Ferrer, Ph.D and Medical Manager. Jonathan and Josephine discuss Pulmonary Arterial Hypertension (PAH), the importance of clinical trials, what they entail, and share information on Janssen’s . Learn more about UNISUS Study with the . Learn more about pulmonary hypertension trials at . Follow us on social @phaware Engage for a cure: #phaware Share your story:
info_outline
Dr. Lewis Romer - phaware® interview 460
I'm Aware That I'm Rare: the phaware® podcast
Dr. Lewis Romer discusses his work on the PPHNet's : Mono- vs. Duo-Therapy for Pediatric PAH patients. The Kids Mod PAH study is a research project funded by the NIH that aims to determine the best initial therapy for children with newly diagnosed pulmonary hypertension. The study compares the effectiveness of one medication (sildenafil) versus a combination of two medications (sildenafil and bosentan) in improving the quality of life and functional class of these children. The study team aims to provide enhanced care and support to the participants and their families throughout the...
info_outline
Episode 460 - Lewis Romer, MD
I'm Aware That I'm Rare: the phaware® podcast
Dr. Lewis Romer discusses his work on the PPHNet's : Mono- vs. Duo-Therapy for Pediatric PAH patients. The Kids Mod PAH study is a research project funded by the NIH that aims to determine the best initial therapy for children with newly diagnosed pulmonary hypertension. The study compares the effectiveness of one medication (sildenafil) versus a combination of two medications (sildenafil and bosentan) in improving the quality of life and functional class of these children. The study team aims to provide enhanced care and support to the participants and their families throughout the...
info_outlineHall Skåra is a pulmonary hypertension patient from Norway. He became part of PHA Europe’s staff after his diagnosis. He has helped develop their “White Spots” program, which establishes new PH patient associations in countries where they don’t exist.
In this episode, Hall discusses the first ever PAH Patient Charter that was launched on November 12, 2019 to coincide with PH Awareness Month. The Charter was facilitated and sponsored by Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson and a PAH-expert Steering Committee made up of patients, patient advocates and healthcare professionals. #PAHPatientCharter #phawarenessmonth
Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Never miss an episode with the phaware® podcast app. Follow us @phaware on Facebook, Twitter, Instagram, YouTube & Linkedin Engage for a cure: www.phaware.global/donate #phaware #ClinicalTrials
@actelion_com @EuropePHA @PHAssociation @wginsing @PhDeutschland @LatinosConHP @Hellenic_PH @phsingapore